This official website is maintained by the Notice Administrator under the supervision of Class Counsel in the action titled In re Talis Biomedical Securities Litigation, No. 22-cv-00105-SI (the “Action”) which is pending in the United States District Court for the Northern District of California (the “Court”).
The information contained on this web page is only a summary of information presented in more detail
in the Notice of Pendency of Class Action, (the “Notice”),
which you can access by clicking here. Since
this website is just a summary, you should review the Notice for additional information.
If you are a Class Member, your legal rights will be affected by this litigation whether you act or do not
act.
If you purchased or otherwise acquired common stock issued by Talis Biomedical Corporation (“Talis” or the “Company”) pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company’s February 11, 2021 initial public offering between February 11, 2021 and August 11, 2021, inclusive, and were damaged thereby, you may be affected by this lawsuit.
Please read the Notice carefully.
If you purchased or otherwise acquired common stock issued by Talis Biomedical Corporation (“Talis” or the “Company”) pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company’s February 11, 2021 initial public offering between February 11, 2021 and August 11, 2021, inclusive, and were damaged thereby, you may be affected by this lawsuit.
| WHAT ARE MY OPTIONS? | |
|---|---|
| Do Nothing | Stay in this lawsuit. Await the outcome. Give up certain rights. By doing nothing, you keep the possibility of sharing in any recovery that may result from trial or settlement. But you give up any right you may have to sue the Defendants separately about the issues and claims being raised in this lawsuit, and you will be bound by the outcome of the case. |
| Ask to be excluded by August 20, 2024 | Get out of the lawsuit. Get no benefits from the lawsuit. Keep your rights. If you ask to be excluded from the lawsuit, you will not be bound by what the Court does in this case and will keep any right you might have to sue Defendants separately about the same issues and claims being raised in this lawsuit. If a recovery is later awarded in this case, you would not share in that recovery. Please note, if you decide to exclude yourself from the Class, you may be time-barred from asserting the claims covered by the Action. |
How do I know if I am part of the Class?
By order dated February 9, 2024, the Court certified the following Class of plaintiffs:
All persons or entities that purchased or otherwise acquired common stock issued by Talis
pursuant and/or traceable to the registration statement and prospectus issued in connection with
the Company’s February 11, 2021 initial public offering between February 11, 2021 and August
11, 2021, inclusive, and were damaged thereby.
Excluded from the Class by definition are:
Excluded from the Class are (i) Defendants and any affiliates or subsidiaries thereof; (ii) present
and former officers and directors of Talis and its subsidiaries or affiliates, and their immediate
family members (as defined in Item 404 of SEC Regulation S-K, 17 C.F.R. § 229.404,
Instructions (1)(a)(iii) & (1)(b)(ii)); (iii) Defendants’ liability insurance carriers, and any affiliates
or subsidiaries thereof; (iv) any entity in which any Defendant has or has had a controlling
interest; (v) Talis’s employee retirement and benefits plan(s); and (vi) the legal representatives,
heirs, estates, agents, successors, or assigns of any person or entity described in the preceding
five categories.
The ruling by the Court certifying the Class does not address the merits of this litigation. Rather, the certification of the Class means only that the ultimate outcome of the Action—whether favorable or unfavorable to the Class—will apply in like manner to each Class Member who does not timely elect to be excluded from the Class.
Further Information
For more details regarding this litigation, please reference the documents filed in the case under the Court Documents section of this website. You may also contact the Notice Administrator for further information.
Notice Administrator:
Talis Biomedical Corporation Securities Litigation
c/o A.B. Data, Ltd.
P.O. Box 173064
Milwaukee, WI 53217
Telephone: 1-877-331-0411
Email: info@TalisSecuritiesLitigation.com
Class Counsel:
Evan A. Kubota
BLEICHMAR FONTI & AULD LLP
300 Park Avenue, Suite 1301
New York, NY 10022
1-888-879-9418
Talis Biomedical Corporation Securities Litigation
c/o A.B. Data, Ltd.
P.O. Box 173064
Milwaukee, WI 53217
Telephone: 1-877-331-0411
Email: info@TalisSecuritiesLitigation.com
Class Counsel:
Evan A. Kubota
BLEICHMAR FONTI & AULD LLP
300 Park Avenue, Suite 1301
New York, NY 10022
1-888-879-9418
